论文部分内容阅读
目的观察依达拉奉联合疏血通治疗急性脑梗死的疗效。方法 68例急性脑梗死患者,随机分为对照组32例,观察组36例,均给予降脂药、脱水剂、降压药及各种对症药物等治疗,对照组静脉滴注复方丹参注射液和低分子右旋糖酐,观察组静脉滴注依达拉奉和疏血通。采用简式Fugl-Meyer评定法(FMA)、Batthel指数(MBI)对治疗前后两组患者进行评分。结果对照组显效率68.75%,观察组显效率86.11%。治疗后对照组MBI、FMA评分分别为(71.4±16.7)分、(67.4±9.3)分,观察组MBI、FMA评分分别为(83.7±18.9)分、(76.0±10.2)分。结论依达拉奉联合疏血通治疗急性脑梗死,可显著提高患者的MBI、FMA评分,改善预后。
Objective To observe the curative effect of edaravone combined with Shuxuetong in treating acute cerebral infarction. Methods Sixty-eight patients with acute cerebral infarction were randomly divided into control group (n = 32) and observation group (n = 36). All the patients were given lipid-lowering drugs, dehydrating agents, antihypertensive drugs and various symptomatic drugs. And low molecular weight dextran, the observation group intravenous edaravone and Shuxuetong. The Fugl-Meyer assessment (FMA) and Batthel index (MBI) were used to score the two groups before and after treatment. Results The effective rate was 68.75% in the control group and 86.11% in the observation group. After treatment, MBI and FMA scores in the control group were (71.4 ± 16.7) and (67.4 ± 9.3) points, respectively. The scores of MBI and FMA in the observation group were (83.7 ± 18.9) and (76.0 ± 10.2) points respectively. Conclusion Edaravone combined with Shuxuetong in the treatment of acute cerebral infarction can significantly improve the patient’s MBI, FMA score, improve prognosis.